Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?

Reimbursement has been cited as a key barrier to the adoption of precision medicine into clinical care.¹ This issue has recently attracted attention with the March 2018 Centers for Medicare & Medicaid Services (CMS) national coverage determination on next-generation sequencing tests for patients with advanced cancer.²